MediWound Ltd. (NASDAQ: MDWD) generates its corporate revenue primarily through commercial product sales of its breakthrough biopharmaceutical solutions—such as NexoBrid for non-surgical debridement of severe thermal burns—distributed through strategic global partnerships with commercial entities like Vericel. Additionally, the company earns crucial developmental revenues and non-dilutive funding grants through research contracts awarded by governmental agencies, including the Biomedical Advanced Research and Development Authority (BARDA) and the U.S. Department of War.